Establishment Labs Holdings Inc. · NASDAQ:ESTA
Establishment Labs — Q1 2026 Earnings Presentation
18 slides from Establishment Labs's earnings presentation, May 6, 2026
Slide 1: Establishment Labs: A Women's Health Company
Establishment Labs A Women’s Health Company Peter Caldini CEO January 15, 2026 | 44th J.P Morgan Healthcare Conference 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, pr
Slide 3: Motivated by Women's Health
Motivated by Women’s Health. 90+ 160+ 218+ 4.5 20 Years of Countries Publications Patents Million Devices Global Innovation Setting the Standard in Breast Aesthetics & Reconstruction Strong US Growth & Global Momentum The Future is Motiva Minimally Invasive Industry Tailwinds Support Market Growth R
Slide 4: Designed with Purpose: Unmatched Safety & Performance
Designed with Purpose: Unmatched Safety & SMOOTHSILK® Enhanced biocompatible surface clinically Performance shown to promote low inflammation and low bacterial attachment TRUEMONOBLOC® Unifies the shell, patch, and gel into a single structure. BLUSEAL® A visual indicator that confirms the barrier la
Slide 5: Unmatched Safety & Performance
Unmatched Safety & Performance Motiva® U.S. IDE Study 5-Year Data Primary Augmentation (N=451) 2-year (95% CI) 3-year (95% CI) 4-year (95% CI) 5-year (95% CI) Capsular contracture 0.5% (N=2) 0.5% (N=2) 0.5% (N=2) 0.5% (N=2) (Baker Grade III/IV) Rupture, suspected or confirmed 0.6% (N=1) 0.6% (N=1) 0
Slide 6: 2025 Accelerating Growth & Profitability
2025 Accelerating Growth & Profitability $210.5M – $211.5M Exceptional US Results Revenue1 In First Year 27% Full Year Growth $17M - 17.5M Motiva® US 4th Quarter Revenue1 $64 - 65M $75.5M 4th Quarter Revenue1 Cash Balance1 $45.4 - 45.9M Motiva® US Revenue In First Year1 Positive Adjusted EBITDA Q3 &
Slide 7: Fastest launch in US Breast Aesthetics History
Fastest launch in US Breast Aesthetics History Established a best-in-class organization in 18 months $45.4 - 45.9M Revenue In First Year1 ~20% 1500+ Augmentation Accounts Opened Market Share Exiting 2025 1. Numbers are preliminary and not audited. Subject to change 7
Slide 8: Driving Market Share
Driving Celebrity Partnership 1000 + Patients #1 Fastest Growing Procedure on RealSelf Market Share Got Motiva Implants in connection with the Meghan Trainor campaign 9.2+ Billion Media Impressions 93% Of patients that requested a brand of breast implant asked for Motiva by name1 Meghan Trainor Actu
Slide 9: Continuing to Drive Market Share in the US in 2026
Continuing to Drive Market Share in the US in 2026 2026 Q1 Launch Line Extension Motiva Implant ® Sales Rep Expansion Account Growth of Additional Sizes Reconstruction & Adoption Indication Breast Tissue Preservation 9
Slide 10: Motiva Aesthetic BreastRecon
Motiva Aesthetic BreastRecon ® • Submitted a PMA supplement for Motiva Implants® primary and revision reconstruction indications with FDA in December 2025. Data currently under review with FDA • Motiva Implant approval doubles TAM as recon market is approximately the same size as augmentation • Moti
Slide 11: Redefining Breast Surgery: The Motiva Minimally Invasive Platform
Redefining Breast Surgery: The Motiva Minimally Invasive ® Platform • Designed to preserve breast tissue and breast functionality 1,2 5 • Minimal anesthesia required • Small incisions 3,4 • Quick recovery 1,2 1. Chacon-Quiros M, Sforza M, Solis-Chaves P, et al. The 3-year results of a 100-patient pr
Slide 12: Minimally Invasive Procedures Drive Market Expansion
Minimally Invasive Procedures Drive Market Expansion 1/4 of women An Untapped Market for Breast Augmentation Are more Interested in 55% getting a breast augmentation after learning Willing to pay a about Preservé2 premium Appeals to a segment that historically has had many barriers to traditional br
Slide 13: Motiva Minimally Invasive Driving at least $30M in Revenue in 2026
Motiva Minimally Invasive ® Driving at least $30M in Revenue in 2026 29+ Global Markets 144 Mia Centers Multi-Center Clinical Study In First Year Globally Ongoing • 50+ US Early Experience Accounts Trained • More than double from 2024 • 2027 & Beyond • Formal Launch Q1 2026 13
Slide 14: Market Tailwinds
Market Tailwinds GLP-1 Era of Transparency Smaller Sizes Meghan Trainor Kylie Jenner Kristin Cavallari • The primary factors that have led • 43% knew Meghan Trainor recently • The ballerina & yoga breast are women to consider a breast had a breast augmentation1 trending augmentation are body changes
Slide 15: Continuous Innovation Driving Growth in 2027 & Beyond
Continuous Innovation Driving Growth in 2027 & Beyond US Breast Global Expansion of GEM® Other Reconstruction Minimally Invasive Innovations Platform • Aesthetic Breast • Procedural • Ergonomix2® & Mia Femtech® in the US Reconstruction development • Biosensing • Material sciences 15
Slide 16: Scale Brings Real Operational Leverage
Scale Brings Real Operational Leverage • Expect Revenue Growth of at Least 25% in both 2026 and 2027 • Corporate Infrastructure Built Over 20 Years Manufacturing can Supply 50%+ of Global Market • Gross Margins Higher US, MIS, Pipeline, and Commercial Focus • Operating Expenses Growing Well Below Re
Slide 17: Powering Sustainable Growth Through Innovation
Powering Sustainable Growth Through Innovation Leading Innovation in Breast Aesthetics & Reconstruction Driving Growth in the US Expanding the Market Through Motiva Minimally Invasive Market Growth Tailwinds Significant Leveraged Growth 17
Slide 18: Establishment Labs
Establishment Labs A Women’s Health Company
Establishment Labs Holdings — Q1 2026 Earnings Presentation on 6ix